---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007233"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:53:58.349319+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anika Q3 revenue $40.3M (+2% YoY); net loss ($4.2M); Cingal Phase III hits endpoint

## Summary
- Revenue $40.3M (+2% YoY); OA Pain Mgmt $25.7M (-2%), Joint Preservation $11.8M (+6%), Non-Ortho $2.8M (+27%).
- Net loss ($4.2M) vs net income $0.6M prior year; adjusted net loss ($0.7M); adjusted EBITDA $4.1M vs $5.7M.
- Cingal Phase III (Cingal 19-01) achieved primary endpoint — superiority over steroid alone at 26 weeks; FDA meeting planned.
- Hyalofast pivotal Phase III 96% enrolled (193 patients); full enrollment expected early 2023; PMA filing on track for 2025.
- FY2022 guidance: overall revenue toward upper end of low to mid single-digit growth; OA Pain Mgmt now expected up mid to upper single-digit %.

## SEC filing metadata
- accession: 0001171843-22-007233
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184322007233/0001171843-22-007233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184322007233/f8k_110822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007233
- JSON: https://secwatch.observer/filing/0001171843-22-007233.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007233.txt

## Key facts
- Earnings Releases
  Anika Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $40.3 million, net income ($4.2) million, or ($0.29) per share, EPS ($0.29) per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $40.3 million
  - Net income: ($4.2) million, or ($0.29) per share
  - EPS: ($0.29) per share
  - Result: reported results
  source text: orthopedics, today reported financial results for its third quarter ended September 30, 2022. Third Quarter 2022 Financial Summary Revenue in the third quarter of 2022 was $40.3 million, up 2% compared with $39.5 million in the third quarter of 2021. OA Pain Management 1 revenue of $25.7 million, down 2% Joint Preservation and Restoration revenue of $11.8
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184322007233/0001171843-22-007233-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.